5 Results for "

Carboxyatractyloside

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Carboxyatractyloside" in MCE Product Catalog:

2
Carboxyatractyloside tripotassium
Carboxyatractyloside tripotassium
0 Images
2 Cited Publications
Cat. No.: HY-N1502
CAS No.: 77228-71-8
Synonyms: Gummiferin tripotassium
Category:  

other families Terpenoids Diterpenoids Plants Disease Research Fields Cancer

Target:  

Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel

Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .
loading...
    loading...
View All Sizes
2
Carboxyatractyloside dipotassium
Carboxyatractyloside dipotassium
0 Images
2 Cited Publications
Cat. No.: HY-N2522
CAS No.: 33286-30-5
Synonyms: Gummiferin dipotassium
Category:  

other families Terpenoids Other Diseases Diterpenoids Plants Disease Research Fields

Target:  

Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)

Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
loading...
    loading...
View All Sizes
Semaglutide-d8
Semaglutide-d8
0 Images
Cat. No.: HY-114118S
Target:  

Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Semaglutide-d8 tetraTFA
Semaglutide-d8 tetraTFA
0 Images
Cat. No.: HY-114118S1
Target:  

Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family

Research Areas:  

Neurological Disease Metabolic Disease Cancer

Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
View All Sizes
Carboxyatractyloside dipotassium (Standard)
Carboxyatractyloside dipotassium (Standard)
0 Images
Cat. No.: HY-N2522R
CAS No.: 33286-30-5
Synonyms: Gummiferin dipotassium (Standard)
Category:  

other families Terpenoids Diterpenoids Plants

Target:  

Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS)

Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
loading...
    loading...
View All Sizes
Assay Types